Dare Bioscience Inc reports results for the quarter ended March 31 - Earnings Summary

• Dare Bioscience Inc DARE.OQ reported a quarterly adjusted loss of 50 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -84 cents. The mean expectation of three analysts for the quarter was for a loss of 58 cents per share. Wall Street expected results to range from -68 cents to -49 cents per share.

• Revenue rose 182.6% to $25.43 thousand from a year ago; analysts expected $300.00 thousand.

• Dare Bioscience Inc's reported EPS for the quarter was a loss of 50 cents​.

• The company reported a quarterly loss of $4.37 million.

• Dare Bioscience Inc shares had held steady so far this quarter and lost 7.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 23.7% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Dare Bioscience Inc is $13.00

This summary was machine generated from LSEG data May 14 at 04:11 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)